The Drug-price Transparency for Consumers Act of 2025 adds a new requirement to federal law: direct-to-consumer advertisements for prescription drugs and biological products that are payable under Medicare or Medicaid must include a pricing disclosure. The disclosure centers on the Wholesale Acquisition Cost (WAC) for a 30-day supply or typical course of treatment and notes that consumer out-of-pocket costs may vary by insurance.
A key exemption applies to drugs with a WAC under $35 for a 30-day supply. The bill also sets up a regulatory pathway, penalties for violations, and public reporting to enforce the price disclosures.
The overarching aim is to empower consumers to compare prices and thereby promote more informed treatment choices and potentially constrain unreasonable price growth.
At a Glance
What It Does
The Secretary must ensure that certain DTC drug ads include pricing information, specifically the WAC for a 30-day supply (or typical course), and note possible insurance-based variation. An exemption exists for drugs under $35 WAC. Final regulations will define presentation and update timelines.
Who It Affects
Pharmaceutical manufacturers that advertise to consumers, media platforms and broadcasters that carry DTC ads, and consumers paying out-of-pocket or via insurance. The rule targets ads for drugs with Medicare/Medicaid coverage.
Why It Matters
Price transparency in ads could shift consumer expectations, enable price shopping, and influence payer dynamics. The provision aligns with broader federal goals to curb wasteful spending and promote competition by making pricing visible at the point of sale decision.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new section to the Social Security Act to address DTC advertising for prescription drugs and biological products. It requires that ads made for products paid for by Medicare or Medicaid disclose the wholesale price for a 30-day supply (or a typical course of treatment) and indicate that the actual price a consumer pays can differ based on their insurance.
There is an exemption for drugs whose WAC is less than $35 for a 30-day supply. The Department of Health and Humans Services would finalize implementing rules within one year of enactment, covering how prices are shown visually and audibly and how often prices may be updated in ads.
Violations would carry civil penalties up to $100,000 per incident, with the penalties administered in the same manner as other penalties. The Secretary may use information about noncompliant manufacturers for public reporting.
Definitions clarify what counts as a prescription drug, a biological product, and what WAC means, and the act authorizes appropriations to carry out these provisions. The intent is to give consumers clear, objective price information at the moment they encounter drug ads, to support informed purchasing decisions and potentially moderate federal drug spending over time.
The Five Things You Need to Know
The bill requires DTC drug ads funded through Medicare/Medicaid to disclose Wholesale Acquisition Cost (WAC) for a 30-day supply.
An exemption exists if the WAC for a 30-day supply is less than $35.
Final implementing regulations must be issued within 1 year of enactment, detailing presentation and update timing for price disclosures.
Violations may incur civil penalties up to $100,000 per incident, with penalties aligned to existing procedures.
The disclosure must note that actual costs may vary due to the consumer’s insurance coverage and plan details.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings and Sense of Congress
Section 2 lays out the rationale for price transparency in pharmaceutical advertising and expresses Congress’s intent to promote competition and informed consumer decision-making. It cites concerns about the lack of accessible price information in advertising and links price visibility to potential reductions in wasteful spending and improved market efficiency.
General Requirement for Pricing Disclosure
This provision requires that, not later than July 1, 2026, direct-to-consumer advertisements for prescription drugs or biological products covered by Medicare or Medicaid include an appropriate pricing disclosure. The disclosure must reference the Wholesale Acquisition Cost for a 30-day supply or, where applicable, a typical course of treatment.
Content of Pricing Disclosure
The pricing disclosure must clearly display the WAC and may explain that the patient’s actual payment can differ based on insurance coverage. This ensures the price presented reflects a standard benchmark while acknowledging the payer- and plan-specific variation in out-of-pocket costs.
Rulemaking
The Secretary must issue final regulations within one year after enactment. Regulations will specify how price information is communicated in each advertising medium (visual and audio components) and the required cadence for updating price data in ads.
Sanctions
Manufacturers or their agents that violate the pricing-disclosure requirement may be fined up to $100,000 per violation. Penalties follow the procedural framework of 1128A, ensuring consistent enforcement.
Public Reporting
The Secretary may utilize information about noncompliant manufacturers to enforce the requirement, enabling public visibility into adherence and noncompliance.
Definitions
Key terms are defined: biological product, prescription drug, and wholesale acquisition cost. The definitions anchor the scope of the pricing disclosures to products approved by the FDA and purchased via standard market channels.
Authorization of Appropriations
The bill authorizes such sums as may be necessary to carry out the pricing-disclosure provisions, ensuring adequate funding for administration, rulemaking, and enforcement.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and caregivers with high-deductible plans benefit from seeing price benchmarks up front, supporting cost-conscious decisions.
- Medicare and Medicaid beneficiaries gain price visibility for drugs covered by their programs, potentially reducing unexpected out-of-pocket costs.
- Private payers and employers benefit from greater price transparency that can improve formulary design and overall cost management.
- Price-data platforms and consumer-education tools gain a clearer data source to help consumers compare options.
- Policy researchers and health economists obtain standardized price data to analyze market dynamics and spending trends.
Who Bears the Cost
- Drug manufacturers and their marketing teams incur costs to adjust ads and implement price-disclosure workflows.
- Media outlets, broadcasters, and digital platforms must display pricing information, requiring policy alignment and potential technical updates.
- Regulatory agencies incur enforcement overhead to monitor compliance and process penalties.
- Smaller or lower-margin drug developers may face higher relative compliance burdens than larger manufacturers.
- Compliance teams within companies must integrate new disclosure requirements into existing advertising review processes.
Key Issues
The Core Tension
The central tension is between providing transparent, comparable pricing information to consumers and the practical costs, complexities, and potential market distortions generated by enforcing a new price-display requirement across diverse advertising channels and product types.
The bill introduces price disclosures that hinge on the Wholesale Acquisition Cost (WAC), which may not reflect the actual price paid after rebates, discounts, or insured copays. This can create a gap between the stated disclosure and the consumer’s real out-of-pocket cost, especially for patients with complex insurance.
The exemption for drugs with a WAC under $35 benefits low-cost products but concentrates the burden on higher-priced therapies, potentially skewing price-visibility toward premium products. There are practical questions about how to present price for combination therapies, multi-ingredient products, or drugs used in non-standard dosing, which could trigger inconsistent disclosures across ads.
Another challenge is ensuring timely updates; price changes between ad buys and regulatory updates could expose manufacturers to penalties if not managed carefully. Finally, implementing uniform disclosure standards across diverse media (TV, digital, print, and social platforms) will require coordination and substantial operational changes for advertisers and platforms.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.